<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433326</url>
  </required_header>
  <id_info>
    <org_study_id>56086</org_study_id>
    <nct_id>NCT03433326</nct_id>
  </id_info>
  <brief_title>Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy</brief_title>
  <acronym>CRYOKID</acronym>
  <official_title>A Multicenter, Open Label, Pilot Study of MK-5172 (Grazoprevir)/MK-8742 (Elbasvir) Without Ribavirin for 12 Weeks in G1b and G4 Patients With HCV-related Cryoglobulinemic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CryoKid is a no-profit, multi-center, single-arm, open-label, pilot study. The study aims to
      evaluate the tolerability of MK-8742 (Elbasvir) / MK-5172 (Grazoprevir) administrated for 12
      weeks without Ribavirin in patients with HCV chronic hepatitis (G1b and G4) and
      cryoglobulinemic nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Weeks</target_duration>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>march 2018-october 2018</time_frame>
    <description>Percentage of participants achieving sustained virologic response 12 weeks after completing treatment (SVR12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR24</measure>
    <time_frame>march 2018-december 2018</time_frame>
    <description>Percentage of participants achieving Sustained Virologic Response 24 weeks after ending study treatment (SVR 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response: improvement or disappearance of MC clinical and biochemical stigmata</measure>
    <time_frame>march 2018-december 2018</time_frame>
    <description>Clinical response: improvement or disappearance of MC clinical and biochemical stigmata at the EOT, at week 12 and week 24 of follow-up. Improvement of the renal function at week 4, week 8, EOT at week 12 and week 24 of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability: Number of participants experiencing an adverse event (AE)</measure>
    <time_frame>march 2018-may 2018</time_frame>
    <description>Tolerability: Number of participants experiencing an adverse event (AE)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Cryoglobulinaemic Glomerulonephritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir/Grazoprevir</intervention_name>
    <description>Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks</description>
    <other_name>MK-8742/MK-5172</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        G1b and G4 patients with HCV-related Cryoglobulinemic Nephropathy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent form signed,

          2. Male or female at least 18 years of age at time of Screening.

          3. Chronic infection with Hepatitis C virus G1b

          4. Chronic infection with Hepatitis C virus G4 naïve, and experienced with baseline HCV
             RNA level &lt;800,000 IU/ml

          5. Metavir score ranging between F0-F4 (with Child-Pugh score ranging from A5 to A6)

          6. Diagnosis of mixed cryoglobulinemia MC (type III or II) according to standard criteria

          7. Chronic renal impairment due to cryoglobulinemic nephropathy. Subjects with renal
             impairment will include CKD Stage 5 (eGFR &lt; 15mL/min or dialysis dependent), CKD Stage
             4 (eGFR 15-29 mL/min), CKD Stage 3 eGFR (30-59 mL/min) and CKD Stage 2 (60-89 mL/min)
             HCV patients.

          8. Albumin level ≥ 3.0 g/dl,

          9. Platelet count ≥ 75 x 103/μL.

        Exclusion Criteria:

          1. Age &lt;18 years

          2. Chronic infection with Hepatitis C virus G4 experienced with baseline HCV RNA level
             &gt;800,000 IU/ml

          3. Patients with HCV genotype 1a, 2, 3, 5, 6,

          4. Coexistence of life-threatening condition(s) unrelated to MC

          5. Diagnosis of malignancy

          6. Pregnancy or breast feeding.

          7. Child-Pugh score &gt; A6

          8. Decompensated cirrhosis or previous decompensation

          9. Platelet count &lt; 75 x 103/μL

         10. Albumin level &lt; 3 g/l

         11. Co-infection with more than one HCV genotype.

         12. Any serious or active medical illness which, in the opinion of the investigator, would
             interfere with subject treatment, assessment, or compliance

         13. HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive)

         14. Known hypersensitivity to Grazoprevir, Elbasvir or any of its components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANNA LINDA ZIGNEGO, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ANNA LINDA ZIGNEGO, MD, PhD</last_name>
    <phone>+390552758</phone>
    <phone_ext>020</phone_ext>
    <email>annalinda.zignego@unifi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MONICA MONTI, PhD</last_name>
    <phone>+390552758</phone>
    <phone_ext>088</phone_ext>
    <email>monica.monti@unifi.it</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Anna Linda Zignego</investigator_full_name>
    <investigator_title>professor of internal medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

